SAN DIEGO, Feb. 27, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained ...
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile ...
SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT ® 4 study demonstrating remission of tardive ...
SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the long-term KINECT ®-4 study demonstrating tardive dyskinesia remission in nearly 60% of ...
“Tardive dyskinesia can significantly impact many aspects of patients’ lives, including daily activities, work or school attendance and social interactions,” said Eiry W. Roberts, M.D., Chief Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results